EarningsQ2 2026 Earnings Report
MX:ESSITYBN Q2 2026 EPS Results
Actual EPS$7.08
Consensus EPS$7.80
Beat/MissMissed by -$0.72
One Year Ago EPS$7.89
MX:ESSITYBN Q2 2026 Revenue Results
Actual Revenue$63.02B
Expected Revenue$62.24B
Beat/MissBeat by +$775.68M
YoY Revenue Growth+2.56%
Earnings Announcement Details
QuarterQ2 2026
Date07/16/2026
TimeBefore Open
Conference CallThursday, July 16, 2026
MX:ESSITYBN Upcoming Earnings
Essity AB's next earnings date is estimated for October 22, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ESSITYBN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced/Neutral. The quarter showed clear operational strengths: volume-driven sales growth across multiple business areas (notably Personal Care, Health & Medical, and Professional Hygiene), progress on cost-savings (SEK 160m COGS savings, SEK 100m SG&A benefit) and strong cash and leverage metrics (SEK 2.8bn cash flow, net debt/EBITDA 1.1). At the same time, notable near-term headwinds persist: Consumer Tissue weakness, margin declines (gross profit margin down ~70bps), acquisition-related cost drag in Personal Care, and expected higher COGS in Q3 from rising pulp, oil-based inputs and energy. Management is implementing price increases and accelerating integration and cost programs to offset these pressures, but timing lags mean margin recovery is not immediate.Company Guidance
Volume-Driven Sales Growth and Net Sales Increase
Net sales increased by roughly SEK 1.0 billion vs. Q2 last year, with organic sales growth of 0.3% and acquisition-related growth of 1.7%. Overall volume grew 1.4%, driving the quarter's sales momentum.
Strong Performance in Personal Care
Personal Care volumes grew 4.3% overall; key subsegments feminine hygiene and incontinence each grew ~6%–7%. Market shares were strengthened across regions (Latin America, North America, Europe).
Health & Medical Momentum
Health & Medical delivered volume growth of ~2.5%, with particularly strong wound care volumes and improved margins in the quarter.
Professional Hygiene Strength
Professional Hygiene volumes grew ~3% with margin improvement in the quarter. Strategic products outperformed the market and launches (e.g., upgraded Tork Mini Jumbo) supported North America performance.
Cost-Savings and Efficiency Delivery
COGS savings of about SEK 160 million and SG&A benefit of ~SEK 100 million in the quarter from the cost program. Management reiterates target of SEK 1 billion+ run-rate savings by year-end.
Resilient Cash Flow and Balance Sheet
Operating cash flow / cash flow was SEK 2.8 billion (a stronger quarter vs. the same period in 2025). Net debt-to-EBITDA remained low at 1.1. Share repurchase program: 2.1 million shares bought for ~SEK 550 million in the quarter.
Innovation and Digital/AI Adoption
Multiple product innovations rolled out (next-gen digitally printed Delta-Cast, TENA Discreet Ultra improvements, Secure Protect in feminine care). AI deployments included Tork Vision Cleaning, AI-enabled digital engineering accelerating product development, and agentic AI in procurement.
Strategic Market Tailwinds
Policy development supportive of holistic solutions: NHS introduced value-based procurement guidance, which is favorable long term for Essity's holistic/total-cost-of-care solutions.
Improved Branded Mix in Tissue
Branded Consumer Tissue sales improved in Europe and product upgrades (e.g., Regio in Mexico, Lotus Confort Sensitive) strengthened brand propositions and mix.
MX:ESSITYBN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed